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Abstract
Transgenic mice with the human thyrotropin-receptor (TSHR) A-subunit targeted to the thyroid are tolerant of the
transgene. In transgenics that express low A-subunit levels (Lo-expressors), regulatory T cell (Treg) depletion using anti-
CD25 before immunization with adenovirus encoding the A-subunit (A-sub-Ad) breaks tolerance, inducing extensive thyroid
lymphocytic infiltration, thyroid damage and antibody spreading to other thyroid proteins. In contrast, no thyroiditis
develops in Hi-expressor transgenics or wild-type mice. Our present goal was to determine if thyroiditis could be induced in
Hi-expressor transgenics using a more potent immunization protocol: Treg depletion, priming with Complete Freund’s
Adjuvant (CFA) + A-subunit protein and further Treg depletions before two boosts with A-sub-Ad. As controls, anti-CD25
treated Hi- and Lo-expressors and wild-type mice were primed with CFA+ mouse thyroglobulin (Tg) or CFA alone before A-
sub-Ad boosting. Thyroiditis developed after CFA+A-subunit protein or Tg and A-sub-Ad boosting in Lo-expressor
transgenics but Hi- expressors (and wild-type mice) were resistant to thyroiditis induction. Importantly, in Lo-expressors,
thyroiditis was associated with the development of antibodies to the mouse TSHR downstream of the A-subunit.
Unexpectedly, we observed that the effect of bacterial products on the immune system is a ‘‘double-edged sword’’. On the
one hand, priming with CFA (mycobacteria emulsified in oil) plus A-subunit protein broke tolerance to the A-subunit in Hi-
expressor transgenics leading to high TSHR antibody levels. On the other hand, prior treatment with CFA in the absence of
A-subunit protein inhibited responses to subsequent immunization with A-sub-Ad. Consequently, adjuvant activity arising
in vivo after bacterial infections combined with a protein autoantigen can break self-tolerance but in the absence of the
autoantigen, adjuvant activity can inhibit the induction of immunity to autoantigens (like the TSHR) displaying strong self-
tolerance.
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Introduction
Transgenic mice with the A-subunit of the human thyrotropin
receptor (TSHR) targeted to the thyroid gland exhibit tolerance to
the transgene. Thus, unlike wild type littermates, the transgenics
do not respond to immunization with a low dose of adenovirus
encoding the autoantigen, the human TSHR A-subunit [1]. Two
transgenic lines express different amounts of TSHR A-subunit in
the thyroid gland and the thymus [2,3]. Because of different
expression levels in the thymus, these mouse lines have different
levels of self-tolerance to the human A-subunit. In low-expressor
A-subunit transgenics (Lo-expressors), tolerance is readily broken
using high doses of A-subunit adenovirus in terms of antibody
generation. In contrast, transgenic mice that express high levels of
the transgene (Hi-expressors) generate little or no TSHR antibody
in response to high dose A-subunit adenovirus immunization, even
if pre-treated with anti-CD25 to deplete regulatory T cells
(Treg)[2,3]. Much higher TSHR antibody levels can be induced
in Hi-expressor transgenics using a more aggressive approach,
namely immunization with A-subunit protein emulsified in
complete Freund’s adjuvant (CFA) followed by A-subunit protein
in incomplete Freund’s adjuvant [1]. However, TSHR antibodies
induced using adjuvant are non-stimulatory and do not induce
hyperthyroidism.
Previously, we observed that Lo-expressor transgenics depleted
of CD25 positive cells before immunization with TSHR adeno-
virus (A-subunit or holoreceptor) developed massive thyroid
lymphocytic infiltration and thyroid damage associated with
hypothyroidism and autoantibody spreading to the other two
major thyroid autoantigens, thyroglobulin (Tg) and thyroid
peroxidase (TPO)[2,4]. This dramatic outcome was not observed
in wild-type littermates depleted of CD25 positive cells and
immunized in the same way. Analysis of T cell and antibody
responses revealed that the basis for thyroid lymphocytic
infiltration in Lo-expressor transgenics (but not in wild-type
littermates) was the presence in the target organ of the
immunogen, namely the human A-subunit [4].
Very high levels of human A-subunit protein are present in
thyroid tissue of the Hi-expressor transgenics [3]. Consequently, it
seemed possible that thyroiditis would be induced in the Hi-
expressor transgenics, assuming that tolerance could be broken at
the T cell level. Both Lo- and Hi-expressor transgenic mice are on
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the BALB/c background. Wild-type BALB/c mice are resistant to
thyroiditis induced by immunization with mouse Tg and adjuvant
(for example lipopolysaccharide). However, Treg depletion before
immunization with Tg and adjuvant induced mild thyroiditis and
Tg antibodies in BALB/c mice [5]. In the present study, we tested
the hypothesis that Treg depleted Hi-expressor A-subunit trans-
genics primed with TSHR A-subunit protein plus adjuvant and
boosted with A-subunit adenovirus would develop thyroiditis,
thyroid damage and antibodies to Tg, as well as antibody
spreading to another thyroid antigen, TPO.
Materials and Methods
Mouse strains
Transgenic mice expressing high and low levels of the human
TSHR A-subunit in the thyroid gland (Hi-expressors and Lo-
expressors) and wild-type littermates were bred at Cedars-Sinai
Medical Center. Generation, characterization and breeding of
these transgenics was described previously [1,2]. The transgenics
were maintained as heterozygotes by breeding them with wild-type
BALB/cJ mice (Jackson Laboratories, Bar Harbor, Maine). In the
present study, Lo-transgenic mice had been crossed to BALB/c for
15 or more generations and Hi expressors for 5–8 generations.
The Mutant Mouse Regional Resource Center, University of
California, Davis has cryopreserved the Lo- and Hi- expressor
transgenics [designated C.Cg-Tg(TG-TSHR)51.9Smcl, #014125)
and C.Cg_Tg(TG_TSHR)50.6Smcl/Mmucd #030109-UCD, re-
spectively].
Reagents for immunization
a. Anti-CD25 was kindly provided by Dr. Y. Nagayama,
Nagasaki University, Nagasaki. Ascites was generated from rat
hybridoma (PC61, American Tissue Culture Collection) in nude
mice. The antibody was purified using protein G and tested in
BALB/c mice (Charles River Laboratory Inc, Yokohama, Japan)
as described [6,7]. These studies were conducted according to the
Guideline for the Care and Use of Laboratory Animals, Nagasaki
University. Treg depletion in Los Angeles was performed by
injecting mice with 500 mg anti-CD25 intraperitoneally (ip) four
days prior to immunization with protein+CFA or adenovirus
immunization (Fig. 1).
b. TSHR-A-subunit protein (TSHR-289) is the recombinant A-
subunit expressed in Chinese Hamster Ovary (CHO) cells,
purified by affinity chromatography [8] and dialyzed against
10 mM Tris, 50 mM NaCl, pH 7.4, before use.
c. Mouse Tg (mTg) was isolated by homogenizing murine
thyroid glands (Pel-Freez, AR) in phosphate buffered saline,
precipitated with 45% saturated (NH4)SO4, followed by dialysis
and fractionation on a Sephadex G-200 column [9].
d. Complete Freund’s Adjuvant (CFA) was obtained from
Sigma Aldrich (F5881; St. Louis, MO).
e. A-subunit adenovirus and control-adenovirus:- Adenovirus
encoding the human TSHR A-subunit (A-sub-Ad) and adenovirus
lacking an insert (‘‘Con-Ad) were previously described [1,10]. Both
viruses were propagated in HEK293 cells, purified by CsCl density
gradient centrifugation and viral particle concentration deter-
mined by absorbance at 260 nm, as described [11]. Immunization
was performed by injecting 561010 particles (in 50 ml) intramus-
cularly (im).
Immunization protocol
Lo- and Hi A-subunit expressor transgenics and wild-type
littermates were immunized as follows (Fig. 1):-
i. Day 0: anti-CD25 (500 mg) ip.
ii. Day 4: human TSHR-A-sub protein (50 mg) emulsified 1:1
with CFA, injected subcutaneously (sc). A second set of
transgenic- and wild-type mice was immunized according to
the same protocol using CFA+Tg (mouse Tg, 40 mg), and a
third set was immunized using CFA alone (emulsified with
phosphate buffered saline without protein).
iii. Day 21: anti-CD25 (500 mg ip).
iv. Day 25: A-sub-Ad im.
v. Day 42: anti-CD25 ip (500 mg).
vi. Day 46: A-sub-Ad-Ad im.
vii. Day 74: euthanasia.
Another group of WT mice was immunized three times with A-
sub-Ad without anti-CD25 or CFA. Controls were WT mice
immunized with adenovirus lacking an insert (Ad-Con) [10].
All animal studies (including breeding and immunization) were
approved by the Institutional Animal Care and Use Committee at
Cedars-Sinai Medical Center and performed with the highest
standards of care in a pathogen-free facility.
TSHR antibodies
Three assays were used to measure TSHR antibodies:-
a. TSHR ELISA antibody binding was evaluated using ELISA
wells coated with purified TSHR A-subunit protein (5 mg/ml,
see above) as described [12]. Duplicate serum aliquots (1:100
dilution) were added to the wells and binding was detected
with horseradish peroxidase-conjugated mouse anti-IgG
(Sigma Aldrich, St. Louis, MO). The signal was developed
with o-phenylenediamine and H2O2 and the optical density
(OD) read at 490 nm. The IgG subclass distribution of TSHR
antibodies was determined using A-subunit (5 mg/ml)-coated
ELISA wells and goat anti-mouse antibodies specific for
mouse IgG1, IgG2a and IgG2b (Caltag, Laboratories,
Burlingame CA). As for IgG class antibodies, the signal was
Figure 1. Protocol for breaking tolerance to the human TSHR in
Hi-expressor A-subunit transgenics by priming with one
injection of CFA+TSHR A-subunit protein CFA followed by
boosting twice with A-subunit-adenovirus. Parallel studies were
performed in Lo-expressor transgenics and wild-type littermates. Four
days before each immunization, mice were injected with anti-CD25 to
deplete regulatory T cells (Treg). The same protocol was used in a
second set of mice to test the outcome of immunization with
CFA+mouse Tg protein or, in a third set, with CFA alone.
doi:10.1371/journal.pone.0043517.g001
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developed with o-phenylenediamine and H2O2. The data for
IgG class antibodies and IgG subclasses are reported as the
OD at 490 nm.
b. Inhibition of TSH binding to the TSHR (TSH binding
inhibition, TBI) using a commercial kit (Kronus, Boise, ID).
Aliquots (25 ml) of mouse serum were incubated with
detergent solubilized TSHR; 125I-TSH was added and the
TSHR-antibody complexes were precipitated with polyethyl-
ene glycol. TBI values were calculated from the formula:-
½1{ TSH binding in test serum  non specific bindingð Þ
= TSH binding in control serum  non specific bindingð |100
c. Linear TSHR antibody epitopes: TSHR peptides: Twenty six
peptides corresponding to amino acids in the human TSHR
extracellular domain and three extracellular loop peptides
[13] were kindly provided by Dr. John Morris (Mayo Clinic,
Rochester MN). Ectodomain peptides are 20 amino acids long
and overlap the subsequent peptide by 5 residues. These
peptides are referred to as A to Z and EC1-EC3 for
ectodomain and extracellular loop peptides, respectively
(Table 1). In addition, peptides for the region downstream
of the A-subunit up to the cell membrane in the mouse TSHR
[14] were purchased from Peptide 2.0 (Chantilly, VA).
As previously described [15], ELISA wells were coated with
individual peptides (10 mg/ml) by incubation in 35 mM NaHCO3,
15 mM Na2CO3, pH 9.3. Test sera (duplicates, diluted 1:100 or
1:500 in high titer sera) were incubated on peptide-coated wells
and reactivity developed with anti-mouse IgG and substrate. The
data are presented as the OD value for binding to a particular
peptide. Peptide assays included A-subunit protein coated wells
and normal mouse serum as negative and positive controls,
respectively.
Autoantibodies to mouse Tg
Serum binding to mouse Tg was measured by ELISA as
previously described [16]. Briefly, ELISA wells were coated with
mouse Tg (1 mg/ml; as described above). Test sera were diluted
1:100, antibody binding was detected with horseradish peroxidase-
conjugated mouse anti-IgG (Sigma Aldrich) and the signal was
developed with o-phenylenediamine and H2O2. The positive
control was serum from a NOD.H2h4 mouse that developed
mouse Tg antibodies on high iodide intake [16]; the negative
control was serum from unimmunized BALB/c mice. The data
are expressed as OD 490 nm.
Autoantibodies to mouse TPO
Serum binding to mouse TPO was measured by flow cytometry
as previously described [16] using Chinese hamster ovary (CHO)
cells stably expressing mouse-TPO [16]. Mouse sera (1:50 dilution)
were incubated with mouse-TPO-CHO cells and binding was
detected using fluorescein isothyocyanate-conjugated affinity
purified goat anti-mouse IgG (Life Techologies, Grand Island,
NY). Cells staining with propidium iodide (1 mg/ml) were
excluded from analysis. Flow cytometry for IgG class antibody
binding to mouse TPO included serum from unimmunized
BALB/c mice (negative control). The positive control was mouse
monoclonal antibody (#15) that recognizes mouse TPO [16].
Flow cytometry was performed (10,000 events) using a FACScan
with CELLQUEST Software (Becton Dickinson, San Jose, CA).
Data are reported as the geometric mean (Geo Mean).
Serum thyroxine and thyroid histology
Total thyroxine (T4) was measured in undiluted mouse serum
(25 ml) by radioimmunoassay using a kit (Siemens Healthcare
Diagnostics, Los Angeles, CA). Control values (mean+2SD).
Thyroids were fixed in buffered formaldehyde (pH 7.4), paraffin-
embedded and serial sections were stained with hematoxylin and
Table 1. TSHR peptides used to investigate recognition of
linear antibody in the present and previous studies (for
example [15]).
Peptide Residues TSHR amino acids hu/mo
A 22–41 MGCSSPPCECHQEEDFRVTC hu
B 37–56 FRVTCKDIQRIPSLPPSTQT ‘‘
C 52–71 PSTQTLKLIETHLRTIPSHA ‘‘
D 67–86 IPSHAFSNLPNISRIYVSID ‘‘
E 82–102 YVSIDVTLQQLESHSFYNLS ‘‘
F 97–116 FYNLSKVTHIEIRNTRNLTY ‘‘
G 112–131 RNLTYIDPDALKELPLLKFL ‘‘
H 127–146 LLKFLGIFNTGLKMFPDLTK ‘‘
I 142–161 PDLTKVYSTDIFFILEITDN ‘‘
J 157–176 EITDNPYMTSIPVNAFQGLC ‘‘
K* 172–191 FQGLCNETLTLKLYNNGFTS hum & mo
L 187–206 NGFTSVQGYAFNGTKLDAVY hu
M 202–221 LDAVYLNKNKYLTVIDKDAF ‘‘
N 217–236 DKDAFGGVYSGPSLLDVSQT ‘‘
O 232–251 DVSQTSVTALPSKGLEHLKE ‘‘
P 247–266 EHLKELIARNTWTLKKLPLS ‘‘
Q* 262–281 KLPLSLSFLHLTRADLSYPS hu & mo
R* 277–296 LSYPSHCCAFKNQKKIRGIL hu & mo
289 end A-sub (immunogen)
S 292–311 IRGILESLMCNESSMQSLRQ hu
IRGILESLMCNESSRNSLRQ mo
T 307–326 QSLRQRKSVNALNSPLHQEY hu
RNLRQRKSVNALRGPIYQEY mo
U 322–341 LHQEYEENLGDSIVGYKEKS hu
IYQEYEEDPGDNSVGYKQNS mo
V 337–356 YKEKSKFQDTHNNAHYYVFF hu
YKQNSKFQESPSNSHYYVFF mo
W 352–371 YYVFFEEQEDEIIGFGQELK hu
YYVFFEEQEDEVVGFGQELK mo
X 367–386 GQELKNPQEETLQAFDSHYD hu
GQELKNPQEETLQAFESHYD mo
Y 382–401 DSHYDYTICGDSEDMVCTPK hu
ESHYDYTICGDNEDMVCTPK mo
Z* 397–415 VCTPKSDEFNPCEDIMGYK hu & mo
EC1* 474–494 DLYTHSEYYNHAIDWQTGPGC hu & mo
EC2 561–570 SSYAKVSICLPMDTETPLAL hu
SSYAKVSICLPMDTDTPLAL mo
Ectodomain peptides are referred to as A-Z and extracellular loop peptides as
EC1-2. Peptides corresponding to the mouse TSHR (14) are included from the
end of the A-subunit (the immunogen; residue 289 to the membrane and EC1
and EC2. Abbreviations:- hu, human TSHR residues; mo, mouse TSHR residues;
*identical peptides (human and mouse, hu & mo); amino acid differences in the
mouse TSHR in bold.
doi:10.1371/journal.pone.0043517.t001
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eosin (Research Animal Diagnostic Laboratory, University of
Missouri, Columbia, MO).
Statistical Analyses
The statistical significance of differences between the magnitude
of responses in multiple groups was determined by ANOVA and
testing between two groups by Mann Whitney Rank Sum test or,
when normally distributed, by Student’s t test.
Results
Hi- and Lo-expressor transgenics and wild-type (WT) mice were
depleted of Treg using anti-CD25 4 days before ‘‘priming’’ with
CFA+TSHRA-subunit protein and again before each of two boosts
with A-subunit-adenovirus (A-sub-Ad). In parallel, a second set of
the three mouse strains was primed with CFA+Tg and a third set
with CFA alone, followed by boosting with two A-subunit-Ad
injections (Fig. 1). Sera were tested for antibodies to the TSHR, Tg
and TPO on two occasions:- one week after the first A-sub-Ad
injection (day 32) and a month after the second A-sub-Ad injection
(euthanasia, day 74). Thyroid lymphocytic infiltration (thyroiditis)
and serum T4 were examined at euthanasia. These time intervals
reflect the outcome in CFA+A-subunit protein primed mice of a
single or two boosts of A-sub-Ad (days 32 and 74, respectively).
CFA priming (with or without protein) had unanticipated effects
on the outcome of immunization. Therefore, we consider first the
development of antibodies to the immunogens, namely the TSHR
A-subunit and in some cases Tg, before considering development
of antibodies to TPO, thyroiditis and serum T4.
Induced TSHR antibodies
High levels of TSHR antibody measured by ELISA developed
in all three strains primed with CFA+TSHR A-subunit protein
and boosted once or twice with A-sub-Ad (Table 2; Fig. 2, upper
panel, left). As would be anticipated for a potent immunization
protocol, namely CFA+A-subunit protein, these ELISA levels were
higher than in WT mice immunized without CFA but, rather,
three times with A-sub-Ad and without Treg depletion (Fig. 2,
upper panel, right). Measuring TSHR antibodies by TSH binding
inhibition (TBI) rather than by ELISA provided similar results in
all three strains primed with CFA+A-subunit protein, but with
some differences. Unlike the similar TSHR ELISA antibody levels
(Table 2, Fig. 2, upper panel, left), TBI levels were highest in Lo-
expressor transgenics and significantly greater than in WT
littermates after a single A-sub-Ad immunization (Fig. 2, middle
panel, left). Moreover, TBI levels for WT mice primed with
CFA+A-subunit protein and boosted once with A-sub-Ad were
significantly lower than TBI values in WT mice immunized with
Table 2. Antibodies to the TSHR and Tg induced in transgenic mice expressing high or low levels of the human TSHR A-subunit (Hi
- and Lo- expressors) and wild-type (WT) littermates.
Day Hi-Expressor Lo-Expressor WT WT
aCD25 (26) aCD25 (26) aCD25 (26) None
A-sub-Ad (26) A-sub-Ad (26) A-sub-Ad (26) A-sub-Ad (36)
Priming CFA/A-sub CFA/A-sub CFA/A-sub None
TSHR ELISA 32 1.6460.09 1.8960.07 1.6060.09 0.9260.26
(OD 490 nm) 74 1.2960.27 1.8360.06 1.5960.17 0.8760.25
TBI 32 54.568.5 77.965.7 29.263.8 81.668.3
(% inhibition) 74 38.169.8 73.165.8 48.8611.8 39.169.4
TgAb 32 0.5160.05 0.3960.05 0.3560.06 0.3760.12
(OD 490 nm) 74 0.6060.06 1.2560.10 0.3760.07 0.3260.15
Priming CFA/Tg CFA/Tg CFA/Tg None*
TSHR ELISA 32 0.2660.20 0.1060.01 0.1860.07 0.9260.26
(OD 490 nm) 74 0.0860.02 0.3660.21 0.7560.24 0.8760.25
TBI 32 15.461.5 11.062.2 16.260.9 81.668.3
(% inhibition) 74 13.161.7 27.1610.9 54.5612.2 39.169.4
TgAb 32 1.4760.13 1.6560.11 1.4160.18 0.3760.12
(OD 490 nm) 74 1.5160.11 1.2260.28 1.5060.17 0.3260.15
Priming CFA/PBS CFA/PBS CFA/PBS None*
TSHR ELISA 32 0.1160.02 0.1260.04 0.2660.12 0.9260.26
(OD 490 nm) 74 0.1960.03 0.6260.36 0.9060.20 0.8760.25
TBI 32 21.660.1 5.062.1 14.362.8 81.668.3
(% inhibition) 74 21.060.4 36.2617.5 63.366.9 39.169.4
TgAb 32 0.5460.17 0.3960.06 0.5160.09 0.3760.12
(OD 490 nm) 74 0.6060.02 0.6360.26 0.5360.08 0.3260.15
The data are shown graphically in Fig. 2. Values are the Mean+SEM (5–7 mice) in sera drawn after 32 and 74 days (euthanasia). The upper limits (mean+2 SEM) for wild-
type mice immunized with control-adenovirus (n = 4): TSHR ELISA 0.35 OD; TBI, 26% inhibition; TgAb 0.6 OD. Statistically significant differences are shown in Fig. 2. Bold
indicates positive values. None*: data for mice immunized 36with A-sub-Ad are repeated to facilitate comparison with mice primed with CFA/Tg and CFA/PBS.
doi:10.1371/journal.pone.0043517.t002
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A-sub-Ad (three times) without Treg depletion (middle panel,
extreme left versus right).
Unexpectedly, in all mouse strains primed with CFA without
TSHR A-subunit protein (CFA+Tg or CFA alone), boosting once
with A-subunit-Ad did not induce TSHR antibodies measured by
ELISA or TBI. After a second A-sub-Ad boost, WT mice and some
Lo- (but not Hi) expressor transgenics developed low levels of
TSHR ELISA antibodies and TBI became detectable in WT mice
(Fig. 2, upper panel, middle; Table 2). These greatly reduced
TSHR antibody levels following CFA priming in the absence of A-
subunit protein contrast with (a) the high levels in WT mice that
did not receive CFA but were immunized three times with A-sub-
Ad and without Treg depletion (Fig. 2, extreme right; Table 2);
and (b) previous observations by others and ourselves of similar or
enhanced TSHR antibody levels after Treg depletion [2,6].
Antibodies to mouse Tg and TPO, thyroiditis and serum
T4
Antibodies to Tg were induced and were detectable at high
levels in all three mouse strains primed with mouse CFA+Tg and
subsequently immunized with A-sub-Ad (Fig. 2, lower panel;
Table 2). At euthanasia (but not at day 32), antibodies to Tg were
detected in Lo-expressor transgenics primed with CFA+A-subunit
even though the mice had not been immunized with Tg. (Fig. 2,
lower panel, left; red arrow). Similarly, TPO antibodies, absent at
day 32 (Table 3) were present at euthanasia in some Lo-expressor
transgenics primed with CFA+A-subunit protein, CFA+Tg or
CFA alone (Fig. 3, upper panel, respectively). The presence of
TPO antibodies correlated with spontaneous development of Tg
antibodies in Lo-expressors primed with CFA+A-subunit protein
(Table 2, Fig. 2, lower left panel). In addition, Lo-expressor
transgenics primed with CFA+A-subunit or CFA+Tg had
significantly lower serum T4 levels at euthanasia than wild-type
or Hi-expressor mice immunized in the same way (Fig. 3, bottom
panel; Table 3). The decreased T4 levels in Lo-expressor
transgenics reflect thyroid damage leading to antibody spreading
to other thyroid antigens, namely Tg (in mice not primed with Tg)
and TPO.
A low level of thyroid lymphocyte infiltration occurred in Hi-
expressor transgenics primed with CFA+Tg (Fig. 3), but not in the
same strain primed with CFA+A-subunit or CFA alone. However,
there was no evidence in these transgenics for the development of
antibodies to Tg or TPO and T4 levels were similar to those in
WT littermates immunized in the same way (Fig. 2 and 3; Tables 2
and 3).
TSHR antibody subclasses
The IgG subclass distribution of TSHR antibodies was
determined to investigate differences between transgenic mice
Figure 2. Antibodies to the TSHR and Tg induced in transgenic mice expressing high or low levels of the human TSHR A-subunit (Hi
- and Lo- expressors, respectively) and wild-type littermates. Mice were depleted of CD25-positive cells before priming with (a) CFA+TSHR A-
subunit protein; (b) CFA+mouse Tg or (c) CFA alone. Subsequently, mice received two cycles of anti-CD25+ depletion 4 days before immunization
with A-sub-Ad. Data shown are the Mean+SEM (n= 5–7 mice) in sera drawn after 32 days (striped bars) and after 74 days (black bars; euthanasia).
TSHR protein and TSHR antibodies (ELISA and TBI) are indicated in red; mouse Tg and mouse Tg antibodies are indicated in green. The grey areas
indicate the mean 6 2 SEM for wild-type mice immunized with control-adenovirus (n = 4). Statistical analyses:- Upper panel-TSHR ELISA antibody:
Significantly greater in WT than Hi-expressor mice at day 74 * p = 0.004; #, p = 0.016 (rank sum test).Middle panel - TBI: significantly greater in WT mice
after 65 days than in Hi-expressors at day 65 # p,0.05 (ANOVA), * p,0.001 (t test); ‘ significantly lower than in WT mice immunized three times with
A-sub-Ad p,0.001 (t test). Lower panel - Tg antibody: *, p,0.05 versus Hi-expressor and WT mice (ANOVA, p,0.5).
doi:10.1371/journal.pone.0043517.g002
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that could possibly contribute to the lack of thyroiditis in Hi
expressor mice primed with CFA+A-subunit protein. However,
there were no significant differences in the levels of A-subunit
antibodies of IgG1 (reflecting T helper 2 cytokines) or IgG2a and
IgG2b (reflecting T helper 1 type cytokines) in Hi- and Lo-
expressor mice or in WT littermates (Fig. 4).
Linear TSHR antibody epitopes
TSHR antibodies detectable by ELISA in mice primed with
CFA+TSHR A-subunit protein and boosted with A-sub-Ad were
tested for recognition of a panel of peptides corresponding to the
human TSHR ectodomain sequence (Table 1). Sera from wild-type
mice as well as Lo- and Hi-expressor transgenics bound strongly to
N-terminal peptides A and B as well as to several other peptides
within the human A-subunit (Fig. 5). Importantly, unlike wild-type
and Hi-expressor transgenics, antibodies in Lo-expressor trans-
genics also bound to ectodomain peptides downstream of the A-
subunit, namely peptides S, Z and EC1. It should be emphasized
that the mice were primed with human A-subunit protein and
boosted with human A-sub-Ad. Consequently, binding to peptides
S, Z and EC1 implies recognition of the mouse TSHR. Because
some of these peptides differ in mice and humans (Table 1),
synthetic peptides corresponding to the non-identical mouse
peptides were purchased. Comparison of binding to the mouse
peptides was similar to binding to human peptides and no
additional linear epitopes were identified (data not shown).
Discussion
Previously we found that massive thyroiditis, associated with
thyroid damage and thyroid antibody spreading to Tg and TPO,
was induced by Treg depletion using anti-CD25 before immuni-
zation with TSHR adenovirus in transgenic mice expressing low,
but not high, levels of the human TSHR A-subunit in the thymus
and thyroid [2,4]. The goal of the present study was to determine
if a potent immunization protocol, namely complete Freund’s
Adjuvant (CFA)+A-subunit protein, followed by boosting with A-
sub-adenovirus in Treg depleted animals could break tolerance
and induce thyroiditis in Hi-expressor transgenics. Although anti-
CD25 depletion could also deplete activated T cells (for example
[17]), all mice received the same treatment and, with some
exceptions attributed to CFA rather than to anti-CD25 (described
below), developed strong antibody responses.
In Treg depleted Hi-expressor transgenics, priming with
CFA+A-subunit protein prior to A-subunit adenovirus immuni-
zation effectively induced TSHR antibodies at much higher levels
than we observed even using high-dose TSHR-adenovirus [1,3].
Indeed, the antibody levels were comparable with those previously
achieved when these mice were primed with CFA+ A-subunit
protein and boosted twice with incomplete Freund’s adjuvant+A-
subunit protein [1]. Despite the induction of strong antibody
responses, neither the Hi-expressor transgenics nor the WT
littermates developed thyroiditis. In contrast, thyroiditis developed
in Lo-expressor transgenics in association with autoantibodies to
Tg in all mice and autoantibodies to TPO in some animals.
The time-line for the development of antibodies to the TSHR,
Tg and TPO is of potential interest. However, it should be
emphasized that TSHR antibodies develop spontaneously in
humans, but not in mice. In the current investigation, as in other
studies (reviewed in [18]), TSHR antibodies are detected after two
immunizations with the TSHR (protein or expressed by in vivo by
adenovirus). Antibodies to Tg and TPO were only observed at
euthanasia, not at the earlier time point, in Lo-expressor
transgenics that developed thyroiditis. In NODH.2h4 mice, Tg
Table 3. TPO antibodies, thyroiditis and serum T4 in Hi-expressor transgenics, Lo-expressor transgenics and WT mice.
Day Hi-Expressor Lo-Expressor WT WT
aCD25 (26) aCD25 (26) aCD25 (26)
A-sub-Ad (26) A-sub-Ad (26) A-sub-Ad (26) A-sub-Ad (36)
Priming CFA/A-sub CFA/A-sub CFA/A-sub None
TPO Ab 32 1.162.9 23.862.6 0.463.0 24.660.8
(Geo Mean) 74 24.062.2 22.4611.0 20.363.6 25.960.7
Thyroiditis (%) 74 0.160.0 76.4612.9 0.160.0 0.160.0
T4 (mg/dL) 74 4.160.4 2.060.8 5.160.6 3.961.0
Priming CFA/Tg CFA/Tg CFA/Tg None*
TPO Ab 32 27.961.4 1.566.0 1.863.2 24.660.8
(Geo Mean) 74 25.562.2 24.6619.6 23.464.9 25.960.7
Thyroiditis (%) 74 4.461.3 50.0616.7 2.162.0 0.160.0
T4 (mg/dL) 74 4.060.4 2.560.4 4.660.6 3.961.0
Priming CFA/PBS CFA/PBS CFA/PBS None*
TPO Ab 32 27.760.6 20.464.8 4.366.5 24.660.8
(Geo Mean) 74 28.464.1 29.9628.0 4.165.0 25.960.7
Thyroiditis (%) 74 0.460.3 52.5619.0 0.160.0 0.160.0
T4 (mg/dL) 74 3.760.4 4.160.5 5.461.6 3.961.0
The data are shown graphically in Fig. 3. Values are the Mean 6 SEM (5–7 mice) in sera drawn after 32 and 74 days (euthanasia). The upper limit (mean+2 SEM) for wild-
type mice immunized with control-adenovirus (n = 4) are:- TPO Ab 15 Geo mean; Thyroiditis, 0.1%; T4, 4.3 mg/dL. Statistically significant differences are shown in Fig. 3.
Bold indicates positive values; italics indicate decreased serum T4. None*: data for mice immunized 36with A-sub-Ad are repeated to facilitate comparison with mice
primed with CFA/Tg and CFA/PBS.
doi:10.1371/journal.pone.0043517.t003
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autoantibodies appeared first followed some time later by TPO
autoantibodies [16]. Taken together, these observations suggest
that thyroid lymphocytic infiltration and thyroid damage, at least
as induced by the protocol involving priming with CFA and A-
subunit protein or Tg, is followed initially by autoantibodies to Tg
and at a later time point by antibodies to TPO.
The basis for the lack of thyroiditis in WT mice and Hi-
expressor transgenics (both on the BALB/c background) is only
partially understood. Unlike Lo-expressor transgenics, WT mice
do not express peptides from the human TSHR in the thyroid that
can be recognized by T cells activated by human A-subunit-Ad [4].
However, BALB/c mice develop mild thyroiditis after Treg
depletion and immunization with adjuvant (lipopolysaccharide)+-
murine Tg [5]. Therefore, we were surprised to find that priming
with CFA+ murine Tg followed by A-sub-Ad did not lead to
thyroiditis in WT mice.
Hi-expressor transgenics should express large amounts of
human TSHR peptides in the thyroid gland. Moreover the
protocol that we used effectively broke self tolerance to the human
A-subunit, at least in terms of TSHR antibodies. Immunization
with CFA and adenovirus would be expected to induce cytokines
of T helper 1 but not T helper 2 responses, interferon-gamma and
interleukin-4, respectively [19,20]. Cytokine responses were not
measured but TSHR antibodies of subclasses IgG2a and IgG2b
were produced in all three mouse strains, consistent with
production of the Th1 cytokine IFN-gamma. Although there
may be other differences in the immune response of the Hi-
expressors, it is possible that unknown thyroid characteristics may
contribute to the inability to induce thyroiditis in these animals.
Why were T4 levels not elevated in WT mice that developed
TBI activity after priming with CFA+A-subunit protein? As we
reported previously, pre-treatment with A-subunit protein (without
CFA) diverted the development of thyroid stimulating antibodies
to non-functional antibodies and attenuated hyperthyroidism [21].
In addition, we used a high dose of A-sub-Ad to break tolerance in
Hi-expressors, which we previously observed also diverted TSHR
antibodies towards the non-stimulatory variety [22]. However,
among the WT mice that received CFA only (without A-subunit
protein), hyperthyroidism developed in a single mouse (T4
11.1 mg/dL), as reflected in the higher (on average) T4 levels
and the wide SEM bar (Fig. 3).
Returning to TSHR antibodies, in previous studies immunizing
WT BALB/c mice with adenovirus expressing either the full-
length (holo) TSHR to the TSHR A-subunit, antibody binding was
only observed to the peptide A, corresponding to the N-terminal
amino acids of the TSHR (residues 22–41; residues 1–21 being the
signal peptide) [15]. In contrast, immunization with CFA+A-
subunit protein followed by IFA+A-subunit protein induced strong
binding to a wider spectrum of peptides, namely peptides B, M, N
and O [15]. Also in previous studies, Treg depleted WT BALB/c
mice immunized with holoTSHR-Ad generated antibodies that
recognized peptides downstream of the A-subunit (peptides W, X
and Y) [4], consistent with the extended length of the immunogen.
Lo-expressor transgenics subjected to the same protocol only
Figure 3. Antibodies to TPO, thyroiditis and serum T4 in Hi-expressor transgenics, Lo-expressor transgenics and WT mice
immunized with CFA+TSHR A-subunit protein, CFA+mouse Tg, or CFA alone, followed by two immunizations with A-sub-Ad (see
legend to Fig. 2). Four days prior to each of the three immunizations, mice were treated with anti-CD25 to deplete regulatory T cells. Data shown
are the Mean+SEM (n= 5–7 mice) in sera drawn after 32 days (striped bars) and 74 days (euthanasia; black bars). The grey areas indicate the mean6 2
SEM for wild-type mice immunized with control-adenovirus (n = 4). Statistical analysis:- Middle panel- Thyroiditis: * significantly greater in Lo
expressors primed with CFA+A-sub, Tg or PBS than in Hi-expressor transgenics or wild-type mice (ANOVA on ranks, p,0.05); #, significantly greater
in Hi-expressors primed with CFA+Tg than in the same strain primed with CFA+A-sub or CFA+PBS (ANOVA on ranks, p,0.05). Lower panel: * Serum T4
is significantly lower in Lo-expressor transgenics immunized with CFA+A-sub or CFA+Tg than in Hi-expressor transgenics or wild-type mice (p,0 05,
ANOVA).
doi:10.1371/journal.pone.0043517.g003
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developed antibodies to peptide X [4]. In the present study,
immunization restricted to the A-subunit (whether protein+CFA
or A-subunit adenovirus) induced a similar peptide recognition
profile in WT mice and both transgenic lines, namely peptides A,
B and N and (in some mice) peptide R.
The most interesting and novel finding in the current
investigation came from Lo-expressor TSHR-A-subunit trans-
genics that developed thyroiditis after immunization with CFA+A-
subunit protein followed by A-sub-Ad: when examined at
euthanasia, sera from some of these mice had antibody binding
to TSHR peptides not present in the immunogen, namely peptides
S, Z and EC1 downstream of the A-subunit, and only represented
by the naturally occurring mouse TSHR in vivo. These observations
clearly indicate a breakdown in tolerance to the mouse TSHR.
Moreover, the peptides recognized, albeit at low level, differ from
those induced by immunization with the holoTSHR-Ad (see
above). Sera from all mice tested for reactivity to TSHR peptides
had antibodies to mouse Tg; however, there is no homology
between the downstream peptides (S,Z or EC1) and mouse Tg.
More importantly, the present data are the first to demonstrate
antibody recognition of linear epitopes on the mouse TSHR.
A number of other potentially important observations were
made which have implications for the role of infections in breaking
self-tolerance. In particular, priming with CFA+Tg or PBS inhibited
induction by A-subunit adenovirus of TSHR antibody measured
by ELISA or TBI. This inhibition was most potent in mice with
the greatest self-tolerance to the A-subunit (Hi-expressors) and was
lower in WT mice. The effect could not be explained in terms of
antigenic competition because it was observed in mice primed with
CFA+Tg as well as in mice primed with CFA alone. On the other
hand, TSHR antibodies were induced in Hi-expressor transgenics
at levels far higher than previous achieved using A-subunit
adenovirus without CFA+ A-subunit protein priming [1,2].
To summarize, in transgenic mice expressing low intrathyroidal
and intrathymic levels of the human TSHR A-subunit (Lo-
expressors), the combination of Treg depletion plus immunization
with a bacterial adjuvant+TSHR A-subunit protein followed by A-
subunit adenovirus immunization broke self tolerance to the
TSHR leading to thyroid lymphocytic infiltration. However, Hi-
expressor trangenics, like WT BALB/c mice, remained resistant to
the induction of thyroiditis. A novel finding for Lo-expressor
transgenics was the spontaneous development of antibodies to the
mouse TSHR downstream of the A-subunit. Unexpectedly, we found
that the effect of bacterial products on the immune system is a
‘‘double-edged sword’’. One the one hand, self tolerance was
effectively broken as reflected in the high levels of TSHR
antibodies induced by priming with A-subunit+Complete Freund’s
adjuvant (CFA) priming and A-subunit adenovirus immunization
in Hi-expressor transgenics. On the other hand, prior immuniza-
tion with CFA, an emulsion of mycobacteria in oil, strongly
inhibited responses to subsequent immunization with A-subunit
Figure 4. IgG subclasses of TSHR antibodies in Hi- and Lo
expressor A-subunit transgenic mice and WT littermates
injected with anti-CD25 before immunization with TSHR A-
sub protein+CFA and two subsequent injections of human
TSHR A-subunit-adenovirus. ELISA plates were coated with TSHR A-
subunit protein and serum binding was detected using goat anti-
mouse IgG1, IgG2a and IgG2b. Data are shown for the mean+SEM OD
490 nm in ELISA for 4 WT mice, 7 Lo-expressor transgenics and 5 Hi-
expressor transgenics.
doi:10.1371/journal.pone.0043517.g004
Figure 5. Linear TSHR antibody epitopes recognized by Hi- and
Lo expressor A-subunit transgenic mice and wild-type litter-
mates injected with anti-CD25 before immunization with TSHR
A-sub protein+CFA and two subsequent injections of human
TSHR A-subunit-adenovirus. Antibody binding was studied to ELISA
wells coated with synthetic peptides encompassing the human TSHR
ectodomain (peptides A to Z) and two extracellular loops (EC1 and
EC2)(amino acid sequences in Table 1). A dashed line indicates the last
peptide (‘‘R’’) in the human TSHR A-subunit. The shaded area (to the
right) includes the human peptides downstream of the A-subunit (S to
Z, EC1 and E2); antibody binding to peptides in this region implies
recognition of the mouse TSHR. The data for individual mice are shown
as the OD binding value (490 nm) for each peptide (black circles) and to
TSHR A-sub protein (black bar). The number of mice studied in each
group is given in parentheses.
doi:10.1371/journal.pone.0043517.g005
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adenovirus. Consequently, adjuvant activity arising naturally in
vivo after bacterial infections could break self tolerance if combined
with the autoantigen. However, in the absence of the autoantigen,
prior adjuvant activity may inhibit responses to autoantigens (such
as the TSHR) that exhibit strong self-tolerance.
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